XML 29 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Deficit) - Additional Information (Detail) (USD $)
 12 Months Ended 0 Months Ended 24 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended
Dec. 31, 2013
Dec. 31, 2011
Dec. 31, 2012
May 16, 2006
Oct. 12, 2004
Oct. 16, 2013
IPO [Member]
Jan. 11, 2011
Series D-2 Convertible Preferred Stock [Member]
Dec. 31, 2003
Series A Preferred Stock [Member]
Oct. 12, 2004
Series B Preferred Stock [Member]
Dec. 31, 2013
Series B Preferred Stock [Member]
May 16, 2006
Series C Preferred Stock [Member]
Dec. 31, 2013
Series C Preferred Stock [Member]
Dec. 31, 2013
Series D Preferred Stock [Member]
Jul. 16, 2008
Series D Preferred Stock [Member]
Raven Biotechnologies Inc [Member]
Mar. 31, 2011
Series D Preferred Stock [Member]
Raven Biotechnologies Inc [Member]
Dec. 31, 2013
Series A- One Preferred Stock [Member]
Dec. 31, 2013
Series A- Two Preferred Stock [Member]
May 16, 2010
Series D Two Preferred Stock [Member]
Sep. 19, 2008
Series D Two Preferred Stock [Member]
Dec. 31, 2013
Series D Two Preferred Stock [Member]
Dec. 31, 2013
Undesignated Preferred Stock [Member]
Stockholders Equity [Line Items]                                          
Number of shares issued or sold           5,000,000 18,427,388 34,239,374 71,401,237   110,952,217             6,916,110 38,337,678    
Proceeds from issuance of convertible preferred stock   $ 12,014,816           $ 34,000,000 $ 30,300,000   $ 44,900,000               $ 24,800,000    
Price per share           $ 16.00   $ 1.00                          
Related offering costs                 238,000   101,246               156,788    
Shares of common stock allocated       10,003,300 13,604,016                                
Shares issued to acquire entity                           12,466,039 14,446,227            
Purchased shares                                   518,708 2,875,327    
Exercise price                                       0.65  
Proceeds from sale of shares             12,000,000                            
Accrued noncumulative dividends on preferred stock                   $ 0.0341   $ 0.0324 $ 0.0522     $ 0.08 $ 0.08     $ 0.0522  
Convertible preferred stock series                   1.14   1.00 1.00     1.506 1.00     1.00  
Conversion price of preferred stock                   $ 6.95   $ 7.70 $ 12.20     $ 12.39 $ 18.77     $ 12.20  
Additional shares sold under over-allotments Option to underwriter           750,000                              
Proceeds from initial public offering net of expenses           $ 83,800,000                              
Reverse stock split 1-for-18.7739                                        
Common stock, shares authorized 125,000,000   425,000,000                                    
Undesignated preferred stock, shares authorized                                         5,000,000
Undesignated preferred stock, par value                                         $ 0.01
Undesignated preferred stock, shares issued                                         0
Undesignated preferred stock, shares outstanding                                         0